Extraordinary gene transfer between cells observed
MEDIA RELEASE
7 January 2015
Extraordinary gene
transfer between cells observed
Tumour cells without mitochondrial DNA form tumours only after importing replacement DNA from surrounding cells.
A fundamentally new biological process involving gene transfer between cells was published today in the leading biological journal Cell Metabolism by a team headed by Professor Mike Berridge from the Malaghan Institute of Medical Research, Wellington New Zealand, and Professor Jiri Neuzil from the Griffith University, Queensland Australia.
In mouse models of breast cancer and melanoma that had had their mitochondrial DNA removed, replacement DNA was acquired from surrounding normal mouse tissue. After adopting this new DNA, the cancer cells went on to form tumours that spread to other parts of the body.
Professor Berridge says the landmark discovery could open up whole new areas of research.
“Our findings overturn the dogma that genes of higher organisms are usually constrained within cells except during reproduction. It may be that mitochondrial gene transfer between different cells is actually quite a common biological occurrence.”
Although other research groups have seen mitochondrial DNA move between cells in the laboratory, the Malaghan team is the first to demonstrate the transfer in an animal tumour model.
Berridge says the research wouldn’t have happened without the extraordinary patience of his research colleague, An Tan.
“A normal person would have terminated the experiment after a week, before this effect was observed, thinking that the tumour cells without mitochondrial DNA weren’t going to grow. But Tan kept monitoring them for more than a month and eventually saw tumours starting to grow.”
The next challenge for the team was to find out how this was possible.
“Initially we thought the cells had learned to grow without needing mitochondrial DNA. But when we presented the research at a conference, a well-known scientist asked if we had tested the growing cells to see if they contained mitochondrial DNA. We hadn’t.”
A simple experiment confirmed the presence of mitochondrial DNA and extensive molecular, biochemical and protein analysis with international collaborators established that the mitochondrial DNA had, in fact, been obtained from non-tumour cells. The latest genetic sequencing technologies were used to confirm that the adopted mitochondrial DNA was distinct from that of the original tumour, but identical to surrounding non-tumour cells.
The research lays important groundwork for understanding human diseases other than cancer, since defective mitochondrial DNA is known to account for around 200 diseases and is implicated in many more. It could also usher in a new field where synthetic mitochondrial DNA is custom-designed to replace defective genes.
“This appears to be a basic physiological mechanism in the body that no one has seen before because they lacked the exploratory tools. Whether this new phenomenon is important in tumour formation is still unclear, but we are interested in pursuing the research to see if the transfer occurs more widely in the body. Preliminary evidence indicates it may be a common occurrence in the brain.”
Many copies of mitochondrial DNA, a small circular bacterial-like genome, are found inside each mitochondria. This DNA encodes key proteins in the mitochondrial machinery that converts energy from food into a form of chemical energy that is particularly important for brain and muscle function.
Mitochondrial DNA is unrelated to nuclear DNA, which encodes a person’s primary genetic instructions, including characteristics such as hair colour, height and sex. Mitochondrial DNA is inherited solely from a person’s mother – a trait that has been used to trace all living humans back to a common ancestor who lived in Africa 60 –70,000 years ago.
MEDIA
NOTES
Cell
Transfer
Why the
Embargo?
Professor Berridge’s paper will be
published in the leading international biological journal Cell Metabolism at noon EST, in Maryland
USA, on 6 January; 18 hours behind New
Zealand.
About the Malaghan Institute of Medical
Research
We are New
Zealand’s leading vaccine and immunology research
institute, based at Victoria University of Wellington’s
Kelburn campus. Our focus is to find cures for cancer,
asthma and allergy, arthritis, multiple sclerosis and
infectious diseases.
Why is this finding
important?
The journey towards new treatments or
cures for diseases such as cancer is underpinned by basic
research. Each finding increases our understanding and
brings cures closer. Professor Berridge’s team are the
first in the world to demonstrate mitochondrial DNA movement
between cells in an animal tumour. This lays important
groundwork for understanding human diseases other than
cancer, since defective mitochondrial DNA is known to
account for around 200 diseases and is implicated in many
more.
What are mitochondria and what do they
do?
Mitochondria are often referred to as the
powerhouses of the cells. They generate the energy that our
cells need to do their jobs.
Related news on
mitochondria
There were reports on 17 December
2014 that the British parliament will consider legislation
for ‘Three-parent babies’ in 2015.
Donor mitochondria (which contain less than one per cent of
a person’s DNA) could be used to prevent inheritance of
associated diseases estimated to affect one in 5,000 of the
population. The baby would not inherit any traits from the
donor other than their metabolic processes.
Related news from the
Malaghan Institute of Medical Research
We are
also leaders in immunotherapy – harnessing the immune
system to beat diseases. In October we patented a new vaccine technology
that can be used to treat asthma and other allergic
diseases.
Professor Berridge BSc, MSc(Hons),
PhD(Auckland)
Cancer Cell Biology Group
Leader
Professor Berridge completed his
postgraduate degree in Cell Biology at the University of
Auckland in 1971. Following postdoctoral research at Purdue
University, USA, and the National Institute for Medical
Research, UK, he returned to Wellington in 1976 as the
second Malaghan Fellow and established the Cancer Cell
Biology Research Group. He recently held a James Cook
Fellowship in the Health Sciences.
ENDS